Oral iron may be considered in patients with mild anaemia (Hb > 11 g/dL) whose disease is clinically inactive, using alternate-day dosing (60–120 mg ferrous salt) to optimize absorption and minimize gastrointestinal side effects. This evidence concerns the gene GSTM1 and anemia.